alexa Myelofibrosis Management Updates
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Hematology & Blood Disorders
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Abdulraheem Yacoub
Accepted Abstracts: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.008
Abstract
Myeloproliferative neoplasms (MPN) are myeloid hematologic neoplasms that are characterized by expansion of terminal myeloid cells (white blood cells, platelet, red blood cells) and their precursors in the bone marrow (BM) and peripheral blood. MPN include primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia and a few other less common neoplasm. The term myelofibrosis (MF) combines primary myelofibrosis and myelofibrotic transformation of other myeloproliferative neoplasms, namely essential thrombocythemia and polycythemia vera, due to the similar disease characteristics and clinical outcomes. MF is manifested by increased interstitial collagen deposits in the BM, extramedullary hematopoiesis which can result in massive enlargement of the spleen, abnormal blood counts, and debilitating symptoms (e.g., fatigue, weakness, abdominal pain, cachexia, weight loss, pruritus, night sweats, and bone pain) which are thought to be caused by the combined effects of massive splenomegaly and elevated levels of pro-inflammatory cytokines. Survival of patients with MF is compromised and ranges from 2 to 11 years depending on defined prognostic factors. The majority of patients suffer a heavy burden of symptoms due to their disease and/or their low blood counts. Traditional therapeutic options are only palliative and include splenectomy, chemotherapy, immunomodulatory drugs and targeted therapies such as Jak-2 inhibitors. Only allogeneic hematopoietic stem cell transplantation can favorably impact the natural disease course of MF but, unfortunately, few patients are eligible for this treatment.The scarcity of therapeutic options is partially attributable to our limited understanding of the key processes driving this malignancy. There have been several advances in the understanding of the disease biology and the available therapeutic interventions.
Biography
Abdulraheem Yacoub is a young physician-scientist and an Assistant Professor of Medicine in the division of Hematology and Oncology at the University of Kansas. He is nationally recognized for his efforts in improving medical care and patient education in the MPN field. He is a recipient of the MPN Heroes Award and a member of the Myeloproliferative Diseases Research Consortium.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords